Melatonin in Acute Stroke
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 2/17/2019 |
| Start Date: | April 2019 |
| End Date: | February 2020 |
| Contact: | Jonathan Greco, DO |
| Email: | jonathan.greco@jax.ufl.edu |
| Phone: | 904-244-9822 |
Role of Melatonin in the Acute Phase of Stroke as Measured by Interleukin 6 Biomarker
This study will measure Interleukin 6 (IL-6), a well-documented inflammatory biomarker that
is increased in the acute phase of stroke, and to compare its levels after the administration
of melatonin - a well-documented anti-inflammatory and anti-oxidant - that regulates
circadian rhythm, which helps promote sleep.
is increased in the acute phase of stroke, and to compare its levels after the administration
of melatonin - a well-documented anti-inflammatory and anti-oxidant - that regulates
circadian rhythm, which helps promote sleep.
Stroke is a major cause of debilitation in the first world, with few therapeutic options when
it comes to improvement in quality of life and morbidity, besides physical and occupational
therapy. It affects people of all nationalities, creeds, and socioeconomic classes through a
narrow array of mechanisms. With all those mechanisms, a common outcome is shared:
derangement of the brain parenchymal architecture. This derangement is non-selective in its
destruction with obscuration of the blood brain barrier and the glymphatic system, and with
bleeding as a common sequela; the oxidative stress of the hemoglobin-heme-iron compound
causing further injury. This study will measure Interleukin 6 (IL-6), a well-documented
inflammatory biomarker that is increased in the acute phase of stroke, and to compare its
levels after the administration of melatonin - a well-documented anti-inflammatory and
anti-oxidant - that regulates circadian rhythm, which helps promote sleep. Any increased time
spent in a restful state because of melatonin increases the clearance of waste products after
a catastrophic event, like in stroke.
it comes to improvement in quality of life and morbidity, besides physical and occupational
therapy. It affects people of all nationalities, creeds, and socioeconomic classes through a
narrow array of mechanisms. With all those mechanisms, a common outcome is shared:
derangement of the brain parenchymal architecture. This derangement is non-selective in its
destruction with obscuration of the blood brain barrier and the glymphatic system, and with
bleeding as a common sequela; the oxidative stress of the hemoglobin-heme-iron compound
causing further injury. This study will measure Interleukin 6 (IL-6), a well-documented
inflammatory biomarker that is increased in the acute phase of stroke, and to compare its
levels after the administration of melatonin - a well-documented anti-inflammatory and
anti-oxidant - that regulates circadian rhythm, which helps promote sleep. Any increased time
spent in a restful state because of melatonin increases the clearance of waste products after
a catastrophic event, like in stroke.
Inclusion Criteria:
- Adult patients admitted to the Neuroscience Critical Care Unit with a confirmed
ischemic stroke
- Patients with a clinical history and examination consistent with an ischemic stroke
(stroke must be confirmed by a brain CT and/or MRI scan)
- Eligible patients will have been treated with TPA and/or thrombectomy.
Exclusion Criteria:
- Prisoners
- Patients with severe cognitive impairment and/or aphasia (if no family member is
available to sign consent)
- Recent (<1 month) infection
- Pregnant females
We found this trial at
1
site
Click here to add this to my saved trials
